Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAG | P20916 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HRAS | P01112 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5308210 | 1.00 | L3MBTL1 (0.54) | L3MBTL1ALDH1A1MAGPKMPOLB | |
| SCHEMBL11281689 | 0.92 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1MAGPKMPOLB | |
| SCHEMBL15012280 | 0.91 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1 | |
| SCHEMBL10832365 | 0.91 | L3MBTL1 (0.45) | L3MBTL1ALDH1A1MAGPKMTMEM97 | |
| SCHEMBL16146024 | 0.90 | L3MBTL1 (0.45) | L3MBTL1ALDH1A1MAGPKMTMEM97 | |
| SCHEMBL11269209 | 0.89 | L3MBTL1 (0.44) | L3MBTL1MAGKMT2A | |
| SCHEMBL8431552 | 0.86 | L3MBTL1 (0.42) | L3MBTL1KMT2A | |
| SCHEMBL7644075 | 0.86 | L3MBTL1 (0.42) | L3MBTL1ALDH1A1MAGPOLBTMEM97 | |
| SCHEMBL10832391 | 0.85 | L3MBTL1 (0.41) | L3MBTL1MAGKMT2AHRASTMEM97 | |
| SCHEMBL7154934 | 0.85 | MEN1 (0.41) | L3MBTL1KMT2ATMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303363-A1 | Preparation and Use of Isolactosamine and Intermediates therefor | GLYCOM A/S (DK) | 2014-10-09 | — | — | US | disclosed |
| EP-1371733-B1 | PROCESS FOR PRODUCING HYALURONIC ACID OR ITS DERIVATIVE | DENKI KAGAKU KOGYO KK (JP) | 2011-05-11 | — | — | EP | disclosed |
| US-7105320-B2 | Process for producing hyaluronic acid or its derivative | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-09-12 | — | — | US | disclosed |
| US-20040132142-A1 | Process for producing hyaluronic acid or its derivative | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1371733-A1 | PROCESS FOR PRODUCING HYALURONIC ACID OR ITS DERIVATIVE | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2003-12-17 | — | — | EP | disclosed |
| US-6562514-B1 | Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries | PINNACLE VRB LIMITED (AU) | 2003-05-13 | — | — | US | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303363-A1 | Preparation and Use of Isolactosamine and Intermediates therefor | GALE, B4GALT1, GNE | L3MBTL1 1527/4885ALDH1A1 889/4885MAG 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.